{"id":"NCT00744497","sponsor":"Bristol-Myers Squibb","briefTitle":"Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer","officialTitle":"A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined With Dasatinib to Docetaxel Combined With Placebo in Castration-Resistant Prostate Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10","primaryCompletion":"2012-08","completion":"2015-07","firstPosted":"2008-09-01","resultsPosted":"2014-02-06","lastUpdate":"2016-10-17"},"enrollment":1930,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Prostatic Neoplasms"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Dasatinib","otherNames":["Sprycel","BMS-354825"]},{"type":"DRUG","name":"Docetaxel","otherNames":[]},{"type":"DRUG","name":"Prednisone","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Dasatinib","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to determine whether survival can be prolonged in patients with castration-resistant prostate cancer who receive dasatinib with docetaxel and prednisone.","primaryOutcome":{"measure":"Overall Survival: Time From Randomization to Date of Death","timeFrame":"From randomization to death or date of last contact (maximum reached: 45 months)","effectByArm":[{"arm":"Placebo","deltaMin":21.2,"sd":null},{"arm":"Dasatinib","deltaMin":21.5,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.9009"}]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":15},"locations":{"siteCount":186,"countries":["United States","Argentina","Australia","Brazil","Canada","Czechia","Finland","France","Germany","Greece","Hungary","India","Ireland","Italy","Mexico","Norway","Peru","Poland","Romania","Russia","South Africa","South Korea","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["24722180","24211163"],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":317,"n":757},"commonTop":["Diarrhoea","Fatigue","Alopecia","Nausea","Oedema peripheral"]}}